E
Elisabeth Souhami
Publications - 13
Citations - 2391
Elisabeth Souhami is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 1981 citations.
Papers
More filters
Journal ArticleDOI
Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia.
Roger A. Fielding,Bruno Vellas,William J. Evans,Shalender Bhasin,John E. Morley,Anne B. Newman,Gabor Abellan van Kan,Sandrine Andrieu,Juergen M. Bauer,Denis Breuille,Tommy Cederholm,Julie Chandler,Capucine De Meynard,Lorenzo M. Donini,Tamara B. Harris,Aimo Kannt,Florence Keime Guibert,Graziano Onder,Dimitris Papanicolaou,Yves Rolland,Daniel Rooks,Cornel C. Sieber,Elisabeth Souhami,Sjors Verlaan,Mauro Zamboni +24 more
TL;DR: Sarcopenia should be considered in all older patients who present with observed declines in physical function, strength, or overall health, and patients who meet these criteria should further undergo body composition assessment using dual energy x-ray absorptiometry with sarcopenia being defined using currently validated definitions.
Journal ArticleDOI
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial
Wenying Yang,Xiaolin Dong,Qingju Li,Zhifeng Cheng,Guoyue Yuan,Ming Li,Jianzhong Xiao,Shenghong Gu,Elisabeth Niemoeller,Lijuan Chen,Lin Ping,Elisabeth Souhami +11 more
TL;DR: To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide ( Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes on metformin with or without a second oral antihyperglycaemic drug (OAD).
Journal ArticleDOI
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial
Xiaoyong Yuan,Xiaohui Guo,Junqing Zhang,Xiaolin Dong,Yibing Lu,Wuyan Pang,Shenghong Gu,Elisabeth Niemoeller,Lin Ping,Gaowei Nian,Elisabeth Souhami +10 more
TL;DR: iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes advancing therapy from basal insulin ± oral antihyperglycaemic drugs is evaluated.
Journal ArticleDOI
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
Rory J. McCrimmon,Philip Holmes,Alice Y Y Cheng,Francesco Giorgino,Vivian Fonseca,Elisabeth Souhami,Agustina Alvarez,Pascaline Picard,Julio Rosenstock +8 more
TL;DR: To explore details of the incidence and rates of daytime and nocturnal hypoglycaemia, levels of hypoglycemia, and relationship to glycated haemoglobin (HbA1c), when comparing iGlarLixi versus premixed biphasic insulin aspart 30 (BIAsp 30) in the SoliMix randomized controlled trial.
Journal ArticleDOI
773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis
Francesco Giorgino,Cristian Guja,Melanie J. Davies,Hasan Aydin,Felipe Lauand,Elisabeth Souhami,Lydie Melas-Melt,Vanita R. Aroda,Julio Rosenstock +8 more
TL;DR: Guja et al. as mentioned in this paper evaluated glycemic and safety outcomes for iGlarLixi with or without existing SGLT2i therapy and found no increased risk of hypoglycemia.